公开(公告)号：US20190290595A1

公开(公告)日：2019-09-26

申请号：US16441872

申请日：2019-06-14

Applicant: Intelgenx Corp.

Inventor： Horst G. Zerbe ,  Rodolphe Obeid ,  Justin W. Conway ,  Nadine Paiement ,  Ludwig Aigner

IPC: A61K9/70 ,  A61K9/00 ,  A61K31/381 ,  A61K31/404 ,  A61K31/47

Abstract: Disclosed is a device and method for treating a neurodegenerative disease or condition associated with neuroinflammation induced by a leukotriene. The device is a film unit dosage form having a film layer and a safe and effective amount of a leukotriene receptor antagonist or leukotriene synthesis inhibitor. The device is configured and formulated to achieve transmucosal and/or enteral delivery of the leukotriene receptor antagonist or leukotriene synthesis inhibitor. The method includes transmucosally and/or enterally delivering to an animal in need of treatment, a safe and effective amount of a leukotriene blocker capable of crossing the blood-brain barrier.

公开(公告)号：US20180228738A1

公开(公告)日：2018-08-16

申请号：US15912103

申请日：2018-03-05

Applicant: Intelgenx Corp.

Inventor： Horst G. Zerbe ,  Rodolphe Obeid ,  Justin W. Conway ,  Nadine Paiement ,  Ludwig Aigner

IPC: A61K9/70 ,  A61K31/47 ,  A61K31/381 ,  A61K31/404

Abstract: Disclosed is a device and method for treating a neurodegenerative disease or condition associated with neuroinflammation induced by a leukotriene. The device is a film unit dosage form having a film layer and a safe and effective amount of a leukotriene receptor antagonist or leukotriene synthesis inhibitor. The device is configured and formulated to achieve transmucosal and/or enteral delivery of the leukotriene receptor antagonist or leukotriene synthesis inhibitor. The method includes transmucosally and/or enterally delivering to an animal in need of treatment, a safe and effective amount of a leukotriene blocker capable of crossing the blood-brain barrier.

公开(公告)号：US20190133925A1

公开(公告)日：2019-05-09

申请号：US16131995

申请日：2018-09-14

Applicant: Intelgenx Corp.

Inventor： Nadine Paiement ,  Horst G. Zerbe ,  Justin W. Conway ,  Rodolphe Obeid ,  Ludwig Aigner ,  Johanna Michael

IPC: A61K9/00 ,  A61K31/47

Abstract: Disclosed is a method of administration and device for the improved bioavailability of leukotriene receptor antagonists. This method and device involve an alkaline surface pH oral film dosage form designed to deliver leukotriene receptor antagonists, such as Montelukast, to the stomach in an amorphous precipitate suspended in aqueous medium. Also disclosed is a device and method for treating a disease, such as a neurodegenerative disease or condition associated with neuroinflammation induced by a leukotriene. The device is a film unit dosage form having an alkaline surface pH film layer and a safe and effective amount of Montelukast. The device is configured and formulated to predominantly achieve enteral delivery of the Montelukast. The method includes enterally delivering to a human or an animal in need of treatment, a safe and effective amount of Montelukast capable of crossing the blood-brain barrier.

公开(公告)号：US20180250240A1

公开(公告)日：2018-09-06

申请号：US15940288

申请日：2018-03-29

Applicant: Intelgenx Corp.

Inventor： Nadine Paiement ,  Horst G. Zerbe ,  Justin W. Conway ,  Rodolphe Obeid

IPC: A61K9/70 ,  A61K31/47 ,  A61K9/00 ,  A61K47/14 ,  A61K47/18 ,  A61K47/10

CPC classification number: A61K9/7007 ,  A61K9/006 ,  A61K31/47 ,  A61K47/10 ,  A61K47/14 ,  A61K47/183 ,  A61K47/36 ,  A61K47/38

Abstract: Disclosed is a method of administration and device for the improved bioavailability of leukotriene receptor antagonists. This method and device involve an alkaline surface pH oral film dosage form designed to deliver leukotriene receptor antagonists, such as Montelukast, to the stomach in an amorphous precipitate suspended in aqueous medium. Also disclosed is a device and method for treating a disease, such as a neurodegenerative disease or condition associated with neuroinflammation induced by a leukotriene. The device is a film unit dosage form having an alkaline surface pH film layer and a safe and effective amount of Montelukast. The device is configured and formulated to predominantly achieve enteral delivery of the Montelukast. The method includes enterally delivering to a human or an animal in need of treatment, a safe and effective amount of Montelukast capable of crossing the blood-brain barrier.

公开(公告)号：US09949934B1

公开(公告)日：2018-04-24

申请号：US15299054

申请日：2016-10-20

Applicant: Intelgenx Corp.

Inventor： Horst G. Zerbe ,  Rodolphe Obeid ,  Justin W. Conway ,  Nadine Paiement ,  Ludwig Aigner

IPC: A61K9/70 ,  A61K31/4704 ,  C07D215/18 ,  A61K31/404 ,  A61K31/381 ,  A61K31/47

CPC classification number: A61K9/7007 ,  A61K9/006 ,  A61K31/381 ,  A61K31/404 ,  A61K31/47

Abstract: Disclosed is a device and method for treating a neurodegenerative disease or condition associated with neuroinflammation induced by a leukotriene. The device is a film unit dosage form having a film layer and a safe and effective amount of a leukotriene receptor antagonist or leukotriene synthesis inhibitor. The device is configured and formulated to achieve transmucosal and/or enteral delivery of the leukotriene receptor antagonist or leukotriene synthesis inhibitor. The method includes transmucosally and/or enterally delivering to an animal in need of treatment, a safe and effective amount of a leukotriene blocker capable of crossing the blood-brain barrier.

公开(公告)号：US10828254B2

公开(公告)日：2020-11-10

申请号：US16146516

申请日：2018-09-28

Applicant: Intelgenx Corp.

Inventor： Nadine Paiement ,  Rodolphe Obeid ,  Justin W. Conway ,  Billal Tir

IPC: A61K9/00 ,  A61K47/38 ,  A61K31/4985

Abstract: An oral film dosage form includes a high viscosity polymer in an amount of from 1% to 5% by dry weight to reduce, modulate and/or control Cmax of an active agent. The high viscosity polymer has a viscosity of from 100 cps to 500 cps as determined at 2% concentration in water by weight at 25° C. using a Brookfield LVF viscometer with spindle no. 2 at 60 rpm.

公开(公告)号：US10722476B2

公开(公告)日：2020-07-28

申请号：US15912103

申请日：2018-03-05

Applicant: Intelgenx Corp.

Inventor： Horst G. Zerbe ,  Rodolphe Obeid ,  Justin W. Conway ,  Nadine Paiement ,  Ludwig Aigner

IPC: A61K9/70 ,  A61K9/00 ,  A61K31/381 ,  A61K31/404 ,  A61K31/47

Abstract: Disclosed is a device and method for treating a neurodegenerative disease or condition associated with neuroinflammation induced by a leukotriene. The device is a film unit dosage form having a film layer and a safe and effective amount of a leukotriene receptor antagonist or leukotriene synthesis inhibitor. The device is configured and formulated to achieve transmucosal and/or enteral delivery of the leukotriene receptor antagonist or leukotriene synthesis inhibitor. The method includes transmucosally and/or enterally delivering to an animal in need of treatment, a safe and effective amount of a leukotriene blocker capable of crossing the blood-brain barrier.

公开(公告)号：US20200101008A1

公开(公告)日：2020-04-02

申请号：US16146516

申请日：2018-09-28

Applicant: Intelgenx Corp.

Inventor： Nadine Paiement ,  Rodolphe Obeid ,  Justin W. Conway ,  Billal Tir

IPC: A61K9/00 ,  A61K31/4985 ,  A61K47/38

Abstract: An oral film dosage form includes a high viscosity polymer in an amount of from 1% to 5% by dry weight to reduce, modulate and/or control Cmax of an active agent. The high viscosity polymer has a viscosity of from 100 cps to 500 cps as determined at 2% concentration in water by weight at 25° C. using a Brookfield LVF viscometer with spindle no. 2 at 60 rpm